# Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B

> **NCT02413203** · NA · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02413203
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02413203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02413203, "Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02413203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*